Phase I/II study of YHI-1001 in combination with Docetaxel in patients with advanced, metastatic or recurrent non-small cell lung cancer who have received platinum-based chemotherapy

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222077

Enrollment

118

Registered

2013-05-10

Start date

2013-05-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with non-small cell lung cancer who have received platinum-based chemotherapy

Interventions

investigational material(s) Generic name etc : YHI-1001+Docetaxel INN of investigational material : Resminostat+Docetaxel Therapeutic category code : 429 Other antitumor agents Dosage and Administrati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients with histologically or cytologically confirmed non-small cell lung cancer (2)Patients who have received platinum-based chemotherapy (3)Patients with ECOG PS of 0-1 (4)Patients who are able to take YHI-1001 orally and do not have GI dysfunction impacting on abosorption of YHI-1001

Exclusion criteria

Exclusion criteria: (1)Patients who have taken HDAC inhibitors or Docetaxel (2)Patients with uncontrolled intercurrent illness

Design outcomes

Primary

Measure	Time frame
PI:Safety PII:Efficacy	—

Secondary

Measure	Time frame
PI:PK PII:Safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026